Zacks: Brokerages Expect Marinus Pharmaceuticals Inc (MRNS) to Announce -$0.29 EPS
Equities research analysts forecast that Marinus Pharmaceuticals Inc (NASDAQ:MRNS) will announce earnings of ($0.29) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Marinus Pharmaceuticals’ earnings. Marinus Pharmaceuticals posted earnings per share of ($0.20) during the same quarter last year, which would indicate a negative year-over-year growth rate of 45%. The company is scheduled to issue its next earnings report on Tuesday, March 5th.
On average, analysts expect that Marinus Pharmaceuticals will report full-year earnings of ($0.93) per share for the current financial year, with EPS estimates ranging from ($0.95) to ($0.90). For the next financial year, analysts forecast that the company will post earnings of ($1.14) per share, with EPS estimates ranging from ($1.35) to ($0.99). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that cover Marinus Pharmaceuticals.
Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its earnings results on Monday, October 29th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.06).
NASDAQ:MRNS traded up $0.79 during midday trading on Friday, reaching $5.31. 1,149,088 shares of the stock traded hands, compared to its average volume of 834,844. Marinus Pharmaceuticals has a 12-month low of $3.31 and a 12-month high of $10.54. The stock has a market capitalization of $183.17 million, a price-to-earnings ratio of -6.64 and a beta of 3.18.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp lifted its stake in shares of Marinus Pharmaceuticals by 190.4% in the second quarter. Bank of New York Mellon Corp now owns 106,560 shares of the biopharmaceutical company’s stock worth $754,000 after buying an additional 69,863 shares in the last quarter. Alps Advisors Inc. purchased a new position in shares of Marinus Pharmaceuticals in the second quarter worth about $416,000. Tekla Capital Management LLC purchased a new position in shares of Marinus Pharmaceuticals in the third quarter worth about $3,362,000. Trexquant Investment LP purchased a new position in shares of Marinus Pharmaceuticals in the second quarter worth about $102,000. Finally, VHCP Management II LLC purchased a new position in shares of Marinus Pharmaceuticals in the second quarter worth about $2,441,000. 68.70% of the stock is currently owned by institutional investors and hedge funds.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.
Featured Story: Consumer Price Index (CPI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.